WO2025114932 - PURIFICATION OF CLOSED-ENDED DNA MOLECULES
National phase entry is expected:
Publication Number
WO/2025/114932
Publication Date
05.06.2025
International Application No.
PCT/IB2024/061963
International Filing Date
27.11.2024
Title **
[English]
PURIFICATION OF CLOSED-ENDED DNA MOLECULES
[French]
PURIFICATION DE MOLÉCULES D'ADN À EXTRÉMITÉ FERMÉE
Applicants **
SANOFI
Inventors
KAUR MANGAT, Khushdeep
GHOSH, Ronit
CHEN, Wei-Chiang
Priority Data
23307105.9
30.11.2023
EP
63/654,761
31.05.2024
US
63/685,618
21.08.2024
US
63/711,988
25.10.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2843 | |
| EPO | Filing, Examination, Granting | 14621 | |
| Japan | Filing, Examination, Granting | 2461 | |
| South Korea | Filing, Examination, Granting | 2797 | |
| USA | Filing, Examination, Granting | 5740 |
Total:
28,462
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides an efficient and scalable method of purifying closed- end DNA (ceDNA) for therapeutic use.[French]
La présente invention concerne un procédé efficace et évolutif de purification d'ADN à extrémité fermée (ceDNA) à usage thérapeutique.